Compare IRMD & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | INNV |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2014 | 2021 |
| Metric | IRMD | INNV |
|---|---|---|
| Price | $99.20 | $8.33 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 44.8K | ★ 337.9K |
| Earning Date | 05-08-2026 | 05-18-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ 1.75 | 0.14 |
| Revenue | $83,814,000.00 | ★ $853,699,000.00 |
| Revenue This Year | $11.99 | $12.85 |
| Revenue Next Year | $9.91 | $8.88 |
| P/E Ratio | ★ $57.61 | $61.36 |
| Revenue Growth | ★ 14.43 | 11.76 |
| 52 Week Low | $47.48 | $2.60 |
| 52 Week High | $107.90 | $10.69 |
| Indicator | IRMD | INNV |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 49.48 |
| Support Level | $97.67 | $5.01 |
| Resistance Level | $98.44 | $9.18 |
| Average True Range (ATR) | 3.24 | 0.72 |
| MACD | -0.50 | -0.20 |
| Stochastic Oscillator | 11.18 | 3.07 |
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.